Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload

European Journal of Haematology

Volumn 88, Issue 5, 2012, Pages 431-438

  Aydinok, Yesim ^a   Unal, Sule ^b   Oymak, Yesim ^c   Vergin, Canan ^c   Türker, Zeynep D ^d   Yildiz, Dilek ^a   Yesilipek, Akif ^d  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ANTAKYA STATE HOSPITAL   (Turkey)

^c Behcet Uz Children's Hospital   (Turkey)

^d AKDENIZ UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Deferasirox; Desferrioxamine; Iron chelation; Iron overload; Thalassemia major

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHELATION THERAPY; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HUMAN; IRON OVERLOAD; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; TRANSFUSION;

BLOOD TRANSFUSION; CHILD, PRESCHOOL; DEFEROXAMINE; FEMALE; HUMANS; IRON OVERLOAD; MALE;

EID: 84859576452     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01769.x     Document Type: Article

References (18)

1. Maria-Domenica C, Alan C, Androulla E, Antonio P, John P, Ali T, eds. Iron overload. In: Guidelines for the Clinical Management of Thalassaemia, 2nd edn, Chapter 3. Nicosia-Cyprus: Published by Thalasaemia International Federation. 2007: 43-4.
2. Porter J. Optimizing iron chelation strategies in b-thalassaemia major. Blood Rev 2009;23:S3-7.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
4. Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992;14:48-56.
5. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1994;89:757.
6. Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sci 2010;1202:123-8.
7. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009;144:4021-6.
8. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006;9:3455-62.
9. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 2008;111:583-7.
10. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Séchaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003;43:565-72.
11. Se′chaud R, Robeva A, Belleli R, Balez S. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol 2008;48:919-25.
12. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557-66.
13. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5years' follow-up. Blood 2011;4:884-93.
14. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458-65.
15. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB. Efficacy and safety of deferasirox doses of >30mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009;147:752-9.
16. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica 2006;91:1343-51.
17. ®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-80.
18. Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, El-Ali A, Roubert B, El-Beshlawy A. Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol 2011;87:355-65.